Vanda Pharmaceuticals
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Vanda Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#311 of 15,742 sponsors by registered trial count).
Vanda Pharmaceuticals: 68 sponsored US clinical trials, 15 recruiting.
Vanda Pharmaceuticals sponsors 68 registered US clinical trials on ClinicalTrials.gov, 15 of them currently recruiting, and 45 completed. 27 of these trials are in Phase 3-4 (later-stage) and 37 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 5 trials.
Top-decile sponsor footprint
Vanda Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#311 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
45 of 49 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
68 total, page 2 of 2
Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS
NCT02231008
An Observational Study to Investigate the Effects of Rapid Transmeridian Travel
NCT02560103
Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.
NCT01637636
Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine
NCT01540500
Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function
NCT01526746
Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy Subjects
NCT01477619
Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients
NCT01495169
Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception
NCT01429116
Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder
NCT01430754
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
NCT01428661
A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects
NCT01402076
Relapse Prevention Study in Patients With Schizophrenia
NCT01291511
Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment
NCT01271387
Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder
NCT01163032
VEC-162 Study in Adult Patients With Primary Insomnia
NCT00548340
VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia
NCT00291187
Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia
NCT00254202
Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers
NCT00490945
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 17 |
| Phase 2 | 20 |
| Phase 3 | 26 |
| Phase 4 | 1 |
What is open in the Vanda Pharmaceuticals pipeline
15 recruiting of 68 indexed (22% open); 45 completed (66%).
Phase mix: 27 late (III/IV) vs 37 early (I/II) (balanced across stages).
Top condition: Schizophrenia (5 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Vanda Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 68 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
Vanda Pharmaceuticals sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 68 trials (± recruiting share)
- Mallinckrodt · 69 trials · 0% recruiting
- Providence Health & Services · 69 trials · 7% recruiting
- Texas Tech University · 69 trials · 17% recruiting
- University of Colorado, Boulder · 69 trials · 22% recruiting
Sponsors near 22% open enrollment (± trial volume)
- Boston University Charles River Campus · 22% recruiting · 104 trials
- St. Jude Children's Research Hospital · 22% recruiting · 410 trials
- ALX Oncology · 22% recruiting · 9 trials
- Biosense Webster · 22% recruiting · 18 trials
Related
What to do with this Vanda Pharmaceuticals page
68 registered trials is a research-attention snapshot, not an endorsement of Vanda Pharmaceuticals or any single study.
- 15 of Vanda Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Schizophrenia is the condition Vanda Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Vanda Pharmaceuticals pipeline card: 68 registered trials from official public datasets.Report a data error.